Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Top Page
Lisata Therapeutics
(NASDAQ:LSTA)
Rating:43Neutral
Price Target:―
Positive Factors
Clinical Milestone
The completion of patient enrollment in the CENDIFOX study marks a significant clinical milestone, with study results expected to provide valuable data on treatment outcomes.
Financial Performance
Lisata announced 3Q24 financial results, posting EPS of ($0.59) compared to our estimate of ($0.77) and consensus of ($0.75).
Licensing Agreement
A licensing agreement with Kuva Labs expands the potential use of certepetide beyond treatment into cancer diagnosis, creating significant added value.
Negative Factors
Earnings Report
Lisata announced 3Q24 financial results, posting EPS of ($0.59) indicating a loss, even though it was better than estimates.
Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.00M
Dividend YieldN/A
Average Volume (3M)12.76K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth7.07%
CountryUS
Employees26
SectorHealthcare
Sector Strength58
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.55
Shares Outstanding8,598,204
10 Day Avg. Volume8,076
30 Day Avg. Volume12,764
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.24
Price to Sales (P/S)0.00
P/FCF Ratio-1.37
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue6.12
Enterprise Value/Gross Profit13.39
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$15.00Price Target Upside500.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Lisata Therapeutics Business Overview & Revenue Model
Company DescriptionLisata Therapeutics (LSTA) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of cardiovascular diseases and other critical health conditions. The company operates primarily in the biotechnology and pharmaceuticals sectors, striving to address unmet medical needs through its proprietary therapeutic platforms and drug candidates.
How the Company Makes MoneyLisata Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company may earn money via partnerships with larger pharmaceutical companies, licensing agreements, and potential sales of its approved therapies. Additionally, Lisata could receive milestone payments and royalties based on the successful development and commercialization of its products. However, as a clinical-stage company, Lisata's revenue generation is typically dependent on the progression of its drug candidates through clinical trials and eventual regulatory approvals.
Lisata Therapeutics Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 5.49%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and financial management improvements, despite some delays and challenges in strategic partnerships and trial enrollments. The company's focus on advancing Certepetide through various trials and securing regulatory designations indicates a strong strategic direction.Q1-2025 Updates
Positive Updates
Decreased Operating Expenses
Operating expenses for Q1 2025 were $5.8 million, an 11.4% decrease from $6.6 million in Q1 2024, driven by lower clinical research and administrative costs.
Significant Progress in Clinical Trials
Lisata has advanced its clinical development portfolio, particularly with its product candidate Certepetide, which showed promising preliminary results in various trials, including ASCEND and Bolster.
Improved Financial Position
Lisata reported a net loss of $4.7 million for Q1 2025, compared to $5.4 million in Q1 2024, indicating improved financial management.
Secured Special Regulatory Designations
Certepetide received multiple special designations from the FDA and EMA, enhancing its regulatory standing and potential market entry.
Positive Preliminary Cohort A Data
Preliminary data from the ASCEND trial showed a positive trend in overall survival and complete responses in the Certepetide-treated group.
Negative Updates
Delayed Data from Cohort B
The ASCEND trial's Cohort B data are delayed due to amendments in the trial protocol, impacting the timeline for complete data analysis.
Challenges in Strategic Partnerships
Lisata faces challenges in securing partnerships, especially for preclinical programs like endometriosis, due to partners seeking clinically ready assets.
Reduced Enrollment in Bolster Trial Second Cohort
The Bolster trial's second cohort enrollment was capped at 20 patients instead of the planned 40, potentially impacting the depth of data.
Company Guidance
During the Lisata Therapeutics First Quarter 2025 Financial Results and Business Update Conference Call, the management team provided extensive guidance on the company's strategic plans and financial metrics. Operating expenses for the quarter totaled $5.8 million, a reduction of $0.8 million or 11.4% year-over-year. Research and development expenses decreased by 19.7% to $2.6 million, while general and administrative expenses saw a modest decline of 3.4% to $3.2 million. The company reported a net loss of $4.7 million, down from $5.4 million the previous year. Lisata holds approximately $25.8 million in cash, cash equivalents, and marketable securities, which is expected to support operations into Q3 2026. The company is advancing its clinical development portfolio, particularly focusing on the product candidate Certepetide targeting advanced solid tumors. Key upcoming milestones include data from Cohort B of the ASCEND trial at the 2025 ESMO GI Congress in July and accelerated data readout from the Bolster trial in mid-2025. Additionally, a $10 million milestone payment is anticipated from Qilu Pharmaceutical upon the first patient dosing in their Phase 3 study of Certepetide.Lisata Therapeutics Financial Statement Overview
Summary
Lisata Therapeutics faces significant financial challenges with ongoing losses and negative cash flows. Despite a strong equity position and no debt, the lack of revenue consistency and high operational costs are critical concerns.Income Statement
Lisata Therapeutics has faced significant challenges with revenue and profitability. The company reported a substantial net loss of $19,985,000 in the most recent year, despite a modest revenue of $1,000,000. Gross profit margin is quite high at 100% due to minimal cost of goods sold, but this is overshadowed by negative EBIT and EBITDA margins, indicating operational inefficiencies. The revenue growth rate is not applicable, given the absence of revenue in the prior year, which highlights volatility in revenue generation.30
Negative
Balance Sheet
The company's balance sheet shows moderate strength with a high equity ratio of 84.5%, and zero total debt suggesting financial prudence in leveraging. However, the return on equity is negative due to ongoing losses, which is a concern. Cash reserves have declined over the years, reflecting the company's cash burn rate amid its losses.45
Neutral
Cash Flow
The cash flow statement reveals a negative free cash flow of $19,356,000, indicating the company is not generating enough cash to cover its expenditures. The operating cash flow to net income ratio is positive, yet the absolute cash flow figures remain negative. The absence of capital expenditures suggests limited investment in growth initiatives.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.00M | 1.00M | 0.00 | 121.37M | 0.00 | 0.00 | Gross Profit |
| 914.00K | 826.00K | -189.00K | 63.77M | -55.00K | -63.00K | EBIT |
| -15.81M | -22.41M | -25.71M | -27.21M | -29.05M | -19.14M | EBITDA |
| -15.34M | -22.23M | -25.52M | -115.20M | -29.15M | -19.08M | Net Income Common Stockholders |
| -19.31M | -19.98M | -20.84M | -54.23M | -27.47M | -8.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 25.83M | 31.25M | 50.53M | 69.23M | 94.97M | 34.57M | Total Assets |
| 28.98M | 35.00M | 54.69M | 73.03M | 97.01M | 36.00M | Total Debt |
| 0.00 | 137.00K | 305.00K | 485.00K | 714.00K | 624.00K | Net Debt |
| -20.22M | -16.07M | -22.29M | -31.67M | -23.93M | -15.89M | Total Liabilities |
| 3.88M | 5.68M | 6.80M | 6.71M | 5.01M | 3.76M | Stockholders Equity |
| 25.36M | 29.57M | 48.15M | 66.58M | 92.25M | 32.50M |
| Cash Flow | Free Cash Flow | ||||
| -17.76M | -19.36M | -20.03M | -21.45M | -22.30M | -8.84M | Operating Cash Flow |
| -17.73M | -19.36M | -20.03M | -21.17M | -22.25M | -8.82M | Investing Cash Flow |
| 16.23M | 13.23M | 10.10M | 28.91M | -54.90M | -7.28M | Financing Cash Flow |
| -87.00K | -206.00K | 385.00K | -224.00K | 85.28M | 18.58M |
Lisata Therapeutics Technical Analysis
Negative
2.50
Price Trends
2.38
Positive
2.41
Positive
2.70
Negative
Market Momentum
0.04
Positive
48.59
Neutral
23.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Negative. The current price of 2.5 is below the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.38, and below the 200-day MA of 2.70, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 48.59 is Neutral, neither overbought nor oversold. The STOCH value of 23.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSTA.
Lisata Therapeutics Risk Analysis
Lisata Therapeutics disclosed 79 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lisata Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $33.40M | ― | -121.65% | ― | -0.71% | -169.29% | |
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% | |
43 Neutral | $22.00M | ― | -56.49% | ― | ― | 7.07% | |
38 Underperform | $17.00M | ― | -19.56% | ― | ― | 98.61% | |
35 Underperform | $25.02M | ― | -246.21% | ― | ― | 44.38% | |
33 Underperform | $22.61M | ― | -78.32% | ― | ― | 47.73% |
* Healthcare Sector Average
Performance Comparison
LSTA
Lisata Therapeutics
2.50
-0.94
-27.33%
IPA
ImmunoPrecise Antibodies
0.70
-0.34
-32.69%
BCAB
BioAtla
0.40
-1.16
-74.36%
ELEV
Elevation Oncology
0.38
-2.60
-87.25%
PMN
ProMIS Neurosciences
0.52
-1.00
-65.79%
Lisata Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Lisata Therapeutics Reports 2024 Financial Results and Updates
Positive
Feb 27, 2025
On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.